Scientific Publications

Browse our collection of scientific publications on Immunotherapy to learn more about the latest research and developments in the field.

Scientific Publications Headers 9

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Ljungman, P., Mikulska, M., de la Camara, R., et al. Bone Marrow Transplant. 2020;55:2071-2076. 

Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers

Gotti, M., Defrancesco, I., D'Angelo, M., et al. Front Immunol. 2020;11:565236.

Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals

Ortiz de Landazuri, I., Egri, N., Muñoz-Sánchez, G., et al. Front Immunol. 2020;11:573179. 

Emerging agents and regimens for multiple myeloma

Yang, Y., Li, Y., Gu, H., et al. J Hematol Oncol. 2020;13:150.

The EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

Tzogani, K., Penttilä, K., Lähteenvuo, J., et al. Oncologist. 2020 Nov 11. Epub ahead of print.

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Ogiya, D., Liu, J., Ohguchi, H., et al. Blood. 2020;136:2334-2345.

Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Ghafouri, S., Timmerman, J., Larson, S., Mead, MD., Bone Marrow Transplant. 2020 Nov 10. Epub ahead of print.

Anti-CD20 treatment for B-cell malignancies: current status and future directions

Klein, C., Jamois, C., Nielsen, T. Expert Opin Biol Ther. 2020 Nov 9. Epub ahead of print.

Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies

Li, L., Chai, Y., Wu, C., Zhao, L. Expert Rev Hematol. 2020 Nov 10. Epub ahead of print.

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Gang, M., Marin, ND., Wong, P., et al. Blood. 2020;136:2308-2318.

Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers

Saini, SK., Ørskov, AD., Bjerregaard, AM., et al. Nat Commun. 2020;11:5660.

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Gaudio, E., Tarantelli, C., Spriano, F., et al. Haematologica. 2020;105:2584-2591.

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Pasquini, MC., Hu, ZH., Curran, K., et al. Blood Adv. 2020;4:5414–5424.

Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel

Spiegel, JY., Dahiya, S., Jain, MD., et al. Blood. 2020 Nov 6. Epub ahead of print.

Description of neurotoxicity in a series of patients treated with CAR T-cell therapy

Belin, C., Devic, P., Ayrignac, X., et al. Sci Rep. 2020;10:18997.

Bispecific antibodies in acute lymphoblastic leukemia therapy

Chitadze, G., Laqua, A., Lettau, M., et al. Expert Rev Hematol. 2020 Nov 4. Epub ahead of print.

Developing Cell Therapies as Drug Products

Ciccocioppo, R., Comoli, P., Astori, G., et al. Br J Pharmacol. 2020 Nov 3. Epub ahead of print.

Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Topp, MS., Gökbuget, N., Zugmaier, G., et al. Cancer. 2020 Nov 3. Epub ahead of print.

Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies

El-Khazragy, N., Ghozy, S., Emad, P., et al. Immunotherapy. 2020 Nov 5. Epub ahead of print. 

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

Couturier, MA., Thomas, X., Raffoux, E., et al. Leuk Lymphoma. 2020 Nov 6.  Epub ahead of print.

Systematic review and meta-analysis on CAR-T therapy in ALL patients

Anagnostou, T., Riaz, IB., Hashmi, SK., et al. Lancet Haematol. 2020;7:e816-e826.

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

Foà, R., Bassan, R., Vitale, A., et al. N Engl J Med. 2020;383:1613-1623.

CAR-T cells: the Chinese experience

Wang, L., Tan Su Yin, E., Zhao, H., et al. Expert Opin Biol Ther. 2020;20:1293-1308. 

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Bekoz, H., Ozbalak, M., Karadurmus, N., et al. Ann Hematol. 2020;99:2565-2576.

Advances in chimeric antigen receptor T cells

Beyar-Katz, O., Gill, S., Curr Opin Hematol. 2020;27:368-377.

Pembrolizumab for the treatment of Hodgkin Lymphoma

Al Hadidi, SA., Lee HJ., Expert Opin Biol Ther. 2020;2:1275-1282. 

Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group

Le Gouill, S., Beldi-Ferchiou, A., Alcantara, M., et al. Lancet Haematol. 2020;7:e798-e807. 

Brentuximab plus nivolumab for older patients with Hodgkin lymphoma

Cheson, BD., Bartlett, NL., LaPlant, B., et al. Lancet Haematol. 2020;7:e808-e815. 

The tumor microenvironment of lymphomas: insights into the potential role and modes of actions of checkpoint inhibitors

Menter, T., Tzankov, A., Dirnhofer, S., Hematol Oncol. 2020 Oct 26. Epub ahead of print.

Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era?

Shah, NN., Ahn, KW., Litovich, CA., et al. Blood. 2020 Oct 29. Epub ahead of print.

Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies

Leick, MB., Maus, MV., Frigault, MJ., Mol Ther. 2020 Oct 29. Epub ahead of print.

Natural Killer Cells in Immunotherapy: Are We Nearly There?

Bachiller, M., Battram, A.M., Perez-Amill, L., Martín-Antonio B., Cancers (Basel). 2020 Oct 27;12:E3139.

Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective

Córdova-Bahena, L., Velasco-Velázquez, M.A., Rev Invest Clin. 2020 Oct 20;73(5). Epub ahead of print.

IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives

Lapenta, C., Gabriele, L., Santini, SM., Vaccines (Basel). 2020 Oct 19;8(4):E617.

Cancer immunotherapy via targeted TGF-β signalling blockade in T H cells

Li, S., Liu, M., Do, MH., et al. Nature. 2020 Oct 21. Epub ahead of print.

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy

de Jonge A.V., Mutis T., Roemer M.G.M., et al. Cancers (Basel). 2020 Oct 20;12(10):E3052.

The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma

Wang, X., Huynh, C., Urak, R., et al. Cancer Immunol Res. 2020 Oct 22. Epub ahead of print.

Human CXCR5 + PD-1 + CD8 T cells in healthy individuals and patients with hematologic malignancies

Hofland, T, Martens, AWJ., van Bruggen, JAC., et al. Eur J Immunol. 2020 Oct 24. Epub ahead of print.

Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia

Contreras, CF., Higham, CS., Behnert, A., et al. Pediatr Blood Cancer. 2020 Oct 24. Epub ahead of print.

Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology

DiNatale, RG., Hakimi, AA., Chan, TA., Hum Mol Genet. 2020 Oct 20;29:R214-R225.

Implications of metabolism-driven myeloid dysfunctions in cancer therapy

Strauss L., Guarneri V., Gennari A., Sica A., Cell Mol Immunol. 2020 Oct 19:1–13. Epub ahead of print.

Early 3+3 trial dose-escalation phase I clinical trial design and suitability for immune checkpoint inhibitors

Rahma, OE., Reuss, JE., Giobbie-Hurder, A., et al. Clin Cancer Res. 2020 Oct 20. Epub ahead of print.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Shah, N., Aiello, J., Avigan, DE., et al. 2020;8:e000734.

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Deng, Q, Han, G., Puebla-Osorio, N., et al. Nat Med. 2020 Oct 5. Epub ahead of print.

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Cappell, KM., Sherry, RM., Yang, JC., et al. Journal of Clinical Oncology. 2020 Oct 6;33021872. Epub ahead of print

Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome

Kittai, AS., Bond, DA., William, B, et al. Blood Adv. 2020;4: 4648–4652

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

Sermer, D, Batlevi, C., Palomba, ML., et al. Blood Adv. 2020;4: 4669–4678

Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy

Chow, VA., Gopal, AK., Gauthier, J., et al. Blood Adv. 2020;4: 4869–4872

How I treat relapsed acute lymphoblastic leukemia in the pediatric population

Hunger, SP., Raetz, EA., Blood. 2020;136:1803–1812

Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia

Boroojerdi, MH., Rahbarizadeh, F, Kozani PS., et al. Med Oncol. 2020;37:100

CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy

Leong, S., Inglott, S., Papaleonidopoulou, F., et al. Blood Adv. 2020;4:4665-4668

Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities

Magnani, CF., Gaipa, G., Lussana, F., et al. J Clin Invest. 2020:138473. Epub ahead of print.

B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives

Sellner, L., Fan, F., Giesen, N., et al. Int J Cancer. 2020;147:2029-2041

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma

Tong C., Zhang, Y., Liu Y., et al. Blood. 2020;136:1632-1644

Bone morphogenetic protein 7 promotes resistance to immunotherapy

Cortez, MA., Masrorpour, F., Ivan, C., et al. Nat. Commun. 2020,11:4840

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

Parker, KR., Migliorini, D., Perkey, E., et al. Cell. 2020;183:126-142.

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Pillarisetti, K., Powers, G., Luistro, L., et al. Blood Adv. 2020;4:4538–4549.

The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome

Foskolou, IP., Barbieri, L., Vernet, A., et al. Blood Adv. 2020;4:4483–4493.

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab

Kichenadasse, G., Miners, JO., Mangoni, AA., et al. J Natl Compr Canc Netw. 2020;18:11911199. 

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy

Gao, Y., Nihira, NT., Bu, X., et al. Nat Cell Biol. 2020;22:1064-1075. 

Immuno-oncology drug development forges on despite COVID-19

Upadhaya, S., Hubbard-Lucey, VM., Yu, JX., Nat Rev Drug Discov. 2020 Sep 18.  Epub ahead of print. 

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Ramos, C.A., Grover NS., Beaven, AW., et al. J Clin Oncol. 2020 Jul 23:JCO2001342. Epub ahead of print. 

Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity

Fultang, L., Booth, S., Yogev, O., et al. Blood. 2020;136:1155–1160. 

Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas

Neuwelt A., Al-Juhaishi T., Davila E., Haverkos B., Blood Adv. 2020;4:4256-4266. 

Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma

Hashmi, H., Mirza, AS., Darwin, A., et al. Blood Adv. 2020;4:4086-4090. 

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Stenger, D., Stief, T.A., Kaeuferle, T., et al. Blood. 2020;136:1407-1418. 

Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting

Ghesquieres, H., Salles, G., J Clin Oncol. 2020;38:3085-3087. 

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Abramson, JS., Palomba, ML., Gordon, LI., et al. Lancet. 2020;396:839-852. 

Exploring the NK cell platform for cancer immunotherapy

Myers, JA., Miller, JS., Nat Rev Clin Oncol. 2020 Sep 15. Epub ahead of print. 

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

Raskov, H., Orhan, A., Christensen, JP., et al. Br J Cancer. 2020 Sep 15. Epub ahead of print. 

Human immunology and immunotherapy: main achievements and challenges

Varadé J., Magadán S., González-Fernández Á., Cell Mol Immunol. 2020 Sep 2:1–24. Epub ahead of print. 

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

Wudhikarnl K., Palomba, ML., Pennisi, M., et al. Blood Cancer J. 2020;10:79. 

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

Cader, FZ., Hu, X., Goh, WL., et al. Nat Med. 2020;26:1468-1479. 

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Biran, N., Ip, A., Ahn, J., et al. Lancet Rheumatol. 2020;2:e603-e612.

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies 

Einsele, H., Briones, J., Ciceri, F., et al. HemaSphere. 2020;4:e423.  
 

Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients 

Fan, F., Yoo, HJ., Stock, S., et al. Int J Cancer. 2020 Jul 19. Epub ahead of print. 

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma 

Shah N., Aiello J., Avigan, DE., et al. Journal for ImmunoTherapy of Cancer. 2020;8:e000734. 

The Emerging Role of Convalescent Plasma in the Treatment of COVID-19 

Psaltopoulou, T., et al. HemaSphere. 2020;4(3):e409. 

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT.

Yakoub-Agha, I., Chabannon, C., Bader, P., et al. Haematologica. 2020;105:297-316.  

Meeting report of the 2nd European CAR T-Cell meeting in 2020

This report provides a summary of the meeting with links to recorded sessions.

  

Scientific Publications Headers 10

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy 

Lekakis, L.J., Moskowitz, C.H., HemaSphere. 2019;3:e295.  

Delivering on the Promise: Innovative Therapies and the Quest for (Real) Patient Benefit 

Doeswijk, R., Hemasphere. 2019;3:e298.  

Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL 

DiNofia, AM., Maude, SL., HemaSphere. 2019;3:e279.  

Meeting report of the 1st European CAR T-Cell meeting in 2019

This report provides a summary of the meeting with links to recorded sessions.

 

Last Updated on Monday 23 November 2020.